Candel Therapeutics
CADL
21 hedge funds and large institutions have $7.44M invested in Candel Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0.2% more ownership
Funds ownership: 18.76% → 18.96% (+0.2%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
23% less capital invested
Capital invested by funds: $9.7M → $7.44M (-$2.26M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWM
Baystate Wealth Management
Boston,
Massachusetts
|
+$206K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$92K |
| 3 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$49.6K |
| 4 |
Renaissance Technologies
New York
|
+$41K |
| 5 |
BlackRock
New York
|
+$14.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$243K |
| 2 |
E
Ergoteles
New York
|
-$28.7K |
| 3 |
Jane Street
New York
|
-$24K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.53K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.24K |
CADL Hedge Fund Activity: Q1 2023 in Review
21 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q1 2023, worth a combined $7.44M — down 23% from $9.7M a quarter earlier.
Fund positioning in CADL was balanced in Q1 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Baystate Wealth Management, opening a new position worth an estimated $206K. The largest seller was Fidelity Investments, cutting an estimated $243K.
- 21 institutional investors held Candel Therapeutics (CADL) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $7.44M of Candel Therapeutics stock for Q1 2023, down 23% quarter-over-quarter.
- 4 funds opened new Candel Therapeutics positions in Q1 2023 and 4 closed out, a net change of 0 holders.
- The largest Candel Therapeutics buyer in Q1 2023 was Baystate Wealth Management, an estimated $206K added.
- The largest Candel Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $243K sold.
Based on aggregated 13F filings for Q1 2023.